Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Gross Margin (2021 - 2025)

Kiniksa Pharmaceuticals International's Gross Margin history spans 5 years, with the latest figure at 89.64% for Q4 2025.

  • For Q4 2025, Gross Margin rose 424.0% year-over-year to 89.64%; the TTM value through Dec 2025 reached 88.54%, up 293.0%, while the annual FY2025 figure was 88.54%, 293.0% up from the prior year.
  • Gross Margin reached 89.64% in Q4 2025 per KNSA's latest filing, up from 88.8% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 123.46% in Q4 2021 to a low of 67.99% in Q2 2021.
  • Average Gross Margin over 5 years is 89.16%, with a median of 88.14% recorded in 2025.
  • The largest YoY upside for Gross Margin was 1588bps in 2022 against a maximum downside of -1894bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 123.46% in 2021, then dropped by -15bps to 104.52% in 2022, then dropped by -15bps to 88.51% in 2023, then dropped by -4bps to 85.4% in 2024, then grew by 5bps to 89.64% in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Gross Margin are 89.64% (Q4 2025), 88.8% (Q3 2025), and 88.14% (Q2 2025).